NeuroSense Therapeutics (NRSN) News Today $1.27 +0.02 (+1.60%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NeuroSense Completes Key ALS Trial PhaseNovember 1 at 4:54 AM | markets.businessinsider.comNeurosense Therapeutics Secures $30 Million Equity DealNovember 1 at 4:54 AM | markets.businessinsider.comNeuroSense Therapeutics Advances ALS Drug Development PlansOctober 29, 2024 | markets.businessinsider.comEXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application SubmissionOctober 28, 2024 | msn.comNeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionOctober 28, 2024 | prnewswire.comNeuroSense’s PrimeC shows microRNA improvement in ALSOctober 25, 2024 | markets.businessinsider.comNeuroSense’s PrimeC Shows Potential in ALS TreatmentOctober 25, 2024 | markets.businessinsider.comNew Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsOctober 24, 2024 | prnewswire.comNeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further UpdatesOctober 15, 2024 | prnewswire.comNeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in CanadaOctober 9, 2024 | prnewswire.comNeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual MeetingOctober 7, 2024 | prnewswire.comNeuroSense Therapeutics Granted Patent for ALS Treatment FormulationSeptember 24, 2024 | marketwatch.comNeuroSense Reports Patent Grant For PrimeC Formulation - Quick FactsSeptember 24, 2024 | markets.businessinsider.comNeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sSeptember 24, 2024 | prnewswire.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleSeptember 24, 2024 | prnewswire.comNeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationAugust 30, 2024 | prnewswire.comNeuroSense Therapeutics (NASDAQ:NRSN) Stock Quotes, Forecast and News SummaryAugust 29, 2024 | benzinga.comNeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceAugust 7, 2024 | prnewswire.comNeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialAugust 1, 2024 | prnewswire.comNeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionJuly 9, 2024 | prnewswire.comNeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugJuly 1, 2024 | prnewswire.comNRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024June 24, 2024 | investorplace.comNeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsJune 24, 2024 | prnewswire.comNeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealJune 21, 2024 | prnewswire.comEvaxion Biotech GAAP EPS of $0.03 beats by $0.53, revenue of $0.05MMay 29, 2024 | msn.comBuy Rating on Neurosense Therapeutics Backed by Promising ALS Treatment ResultsMay 25, 2024 | markets.businessinsider.comNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitMay 20, 2024 | prnewswire.comNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningMay 14, 2024 | prnewswire.comNeuroSense Reports Positive Data Analysis From PARADIGM Trial With PrimeC In ALSMay 7, 2024 | markets.businessinsider.comNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsMay 7, 2024 | prnewswire.comNeuroSense Announces First Quarter 2024 Business UpdateMay 2, 2024 | prnewswire.comNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseApril 22, 2024 | finance.yahoo.comNeuroSense reports positive ALS trial results, trends in biomarkersApril 19, 2024 | investing.comNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingApril 18, 2024 | prnewswire.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | finance.yahoo.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | prnewswire.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementApril 10, 2024 | prnewswire.comNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketApril 9, 2024 | markets.businessinsider.comNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsApril 9, 2024 | prnewswire.comNeuroSense reports significant ALS trial results, year-end financialsApril 7, 2024 | uk.investing.comNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023April 5, 2024 | investorplace.comNeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateApril 5, 2024 | finance.yahoo.comNeuroSense Therapeutics Ltd NRSNMarch 23, 2024 | morningstar.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | prnewswire.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleFebruary 7, 2024 | finance.yahoo.comNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finanznachrichten.deNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsJanuary 9, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJanuary 4, 2024 | finance.yahoo.com Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%. Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). NRSN Media Mentions By Week NRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼0.110.45▲Average Medical News Sentiment NRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼51▲NRSN Articles Average Week Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALXO News Today VRCA News Today SPRO News Today CTXR News Today RAPT News Today ONCO News Today SYRS News Today EPRX News Today CNTB News Today GANX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts